Search results

Skip to results

Type

Status

Last updated

Showing 1 to 4 of 4 results for bleomycin

  1. Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma (TA1059)

    Evidence-based recommendations on brentuximab vedotin (Adcetris) for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma in adults.

    Technology appraisal guidance
    Published
    7 May 2025

    Sections for TA1059

  2. Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse B-cell lymphoma [ID6202]

    In development [GID-TA11164] Expected publication date: 17 September 2025

    Technology appraisal guidance
    In development

  3. Electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma (IPG478)

    Evidence-based recommendations on electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma. This involves injecting a chemotherapy drug into the tumour and using electrical pulses to increase its effect.

    Interventional procedures guidance
    Published
    26 February 2014
    View recommendations

    Sections for IPG478

  4. Electrochemotherapy for metastases in the skin from tumours of non-skin origin and melanoma (IPG446)

    Evidence-based recommendations on electrochemotherapy for metastases in the skin from tumours of non-skin origin and melanoma. This involves applying short, powerful pulses of electricity to the tumour, allowing an anticancer drug to pass through into the cells.

    Interventional procedures guidance
    Published
    27 March 2013
    View recommendations

    Sections for IPG446